• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Vivos Therapeutics Inc. (Amendment)

    2/10/23 4:05:26 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care
    Get the next $VVOS alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

     (Amendment No. 2)

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    VIVOS THERAPEUTICS, INC.

    (Name of Issuer)

     

    Common stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    92859108

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☐ Rule 13d-1(c)
      ☒ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP 92859E108

     

    1.

    Name of Reporting Persons

     

    Coronado V Partners, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐ (b) ☐

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Wyoming

    Number of

    Shares

    Beneficially

    Owned By

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    1,740,000(1)

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    1,740,000(1)

    8.

    Shared Dispositive Power

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,740,000(1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.0%(1)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1) See Item 4.

     

     

     

     

    CUSIP 92859E108

     

    1.

    Names of Reporting Persons

     

    R. Kirk Huntsman 

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐ (b) ☐

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned By

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    2,250,834(1)

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    2,250,834(1)

    8.

    Shared Dispositive Power

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,250,834(1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.0%(1)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1) See Item 4.

     

     

     

     

     

    Item 1(a). Name of Issuer

     

    Vivos Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b). Address of the Issuer’s Principal Executive Offices

     

    7921 Southpark Plaza, Suite 210

    Littleton, Colorado 80120

     

    Item 2(a). Names of Persons Filing

     

    Coronado V Partners, LLC and R. Kirk Huntsman (collectively, the “Reporting Persons”)

     

    Item 2(b). Address of the Principal Business Office, or if none, Residence:

     

    7921 Southpark Plaza, Suite 210

    Littleton, Colorado 80120

     

    Item 2(c). Citizenship

     

    Coronado V Partners, LLC is a Wyoming limited liability company. R. Kirk Huntsman is a citizen of the United States of America.

     

    Item 2(d). Title of Class of Securities

     

    Common stock, $0.0001 par value per share.

     

    Item 2(e). CUSIP Number

     

    92859E108

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    ☐ (a) Broker or Dealer registered under Section 15 of the Exchange Act.
       
    ☐ (b) Bank as defined in Section 3(a)(b) or the Exchange Act.
       
    ☐ (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.
       
    ☐ (d) Investment company registered under Section 8 of the Investment Company Act.
       
    ☐ (e) An Investment adviser in accordance with Rule 13d-1 (b)(1)(ii)(e).
       
    ☐ (f) An employee benefit plan or endowment fund in accordance with Rule 13d 1(b)(1)(ii)(f).
       
    ☐ (g) A Parent Holding Company or control person in accordance with Rule 13d 1(b)(1)(ii)(g).
       
    ☐ (h) A Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act.
       
    ☐ (i) A Church Plan that is excluded from the definition of an investment company under Section 3 (c)(14) of the Investment Company Act.
       
    ☐ (j) Group, in accordance with Rule 13d-1 (b)(1)(ii)(j).
       
      Not applicable.

     

     

     

     

    Item 4. Ownership

     

    The responses to Items 5-10 of the cover pages of this Schedule 13G are incorporated herein by reference.

     

    As of February 10, 2023, Coronado V Partners, LLC and R. Kirk Huntsman may be deemed to beneficially own 1,740,000 shares and 2,250,834 shares, respectively, of the Issuer’s common stock, representing 6.0% and 9.0%, respectively, of the total shares of common stock issued and outstanding. 

     

    The percentages of the shares of common stock held by the Reporting Persons are based on 25,012,119 shares of common stock issued and outstanding as of February 10, 2023.

     

    As of February 10, 2023, Coronado V Partners, LLC is the record holder of 1,740,000 shares of common stock. R. Kirk Huntsman is the record holder of 510,834 shares of common stock. R. Kirk Huntsman is the president of Coronado V Partners, LLC and has voting and investment discretion with respect to the common stock held of record by Coronado V Partners, LLC. As such, Mr. Huntsman may be deemed to have beneficial ownership of the securities held of record by Coronado V Partners, LLC. The 510,834 shares held of record by Mr. Huntsman include 463,334 shares which may be purchased by exercising an option to purchase such shares, which 438,334 option is presently exercisable.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    Not applicable.

      

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 10, 2023

     

      Coronado V Partners, LLC
         
      By: /s/ R. Kirk Huntsman
      Name: R. Kirk Huntsman
      Title: President

     

      /s/ R. Kirk Huntsman
      R. Kirk Huntsman

     

     

     

    Get the next $VVOS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VVOS

    DatePrice TargetRatingAnalyst
    8/13/2021$11.00 → $10.00Buy
    Roth Capital
    More analyst ratings

    $VVOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada

      Transaction brings OSA diagnostic revenue to Vivos, plus Vivos' highly effective OSA treatment options to thousands of potential patients in the greater Las Vegas area Transaction also completes Vivos' business model pivot to target high patient volume centers and higher margin revenues Over $11 million in new financing secured by Vivos, including a senior secured loan from Streeterville Capital and an equity private placement by existing investor New Seneca Partners LITTLETON, Colo., June 11, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leader in delivering and promoting sleep wellness and health through its proprietary, non-invas

      6/11/25 8:30:00 AM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

      Year-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for its Sleep Center of Nevada acquisition and continued advancement of its new marketing and distribution model Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults, and moderate to severe OSA in childr

      5/15/25 4:20:00 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

      LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17)), today announced it plans to release its first quarter 2025 financial results after market close on Thursday, May 15, 2025. The Company will conduct a conference call at 5:00 p.m. (Eastern Time) on May 15, 2025 to review the results and provide an overview of the

      5/14/25 9:15:00 AM ET
      $VVOS
      Medical/Dental Instruments
      Health Care

    $VVOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Vivos Therapeutics with a new price target

      Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $10.00 from $11.00 previously

      8/13/21 1:08:07 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Roth Capital reiterated coverage on Vivos Therapeutics with a new price target

      Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $11.00 from $12.00 previously

      5/18/21 10:44:01 AM ET
      $VVOS
      Medical/Dental Instruments
      Health Care

    $VVOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Huntsman Ronald Kirk

      4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

      11/27/24 4:47:13 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Amman Bradford K.

      4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

      11/27/24 4:43:54 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Sokolow Leonard J

      4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

      6/28/24 8:53:50 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care

    $VVOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

      SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

      11/14/24 4:49:30 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

      SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

      11/14/24 4:05:24 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Vivos Therapeutics Inc.

      SC 13G - Vivos Therapeutics, Inc. (0001716166) (Subject)

      9/24/24 2:59:09 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care

    $VVOS
    SEC Filings

    See more
    • Vivos Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

      6/6/25 5:19:55 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

      5/23/25 8:00:22 AM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

      5/15/25 5:25:05 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care

    $VVOS
    Financials

    Live finance-specific insights

    See more
    • Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada

      Transaction brings OSA diagnostic revenue to Vivos, plus Vivos' highly effective OSA treatment options to thousands of potential patients in the greater Las Vegas area Transaction also completes Vivos' business model pivot to target high patient volume centers and higher margin revenues Over $11 million in new financing secured by Vivos, including a senior secured loan from Streeterville Capital and an equity private placement by existing investor New Seneca Partners LITTLETON, Colo., June 11, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leader in delivering and promoting sleep wellness and health through its proprietary, non-invas

      6/11/25 8:30:00 AM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

      Year-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for its Sleep Center of Nevada acquisition and continued advancement of its new marketing and distribution model Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults, and moderate to severe OSA in childr

      5/15/25 4:20:00 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

      LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17)), today announced it plans to release its first quarter 2025 financial results after market close on Thursday, May 15, 2025. The Company will conduct a conference call at 5:00 p.m. (Eastern Time) on May 15, 2025 to review the results and provide an overview of the

      5/14/25 9:15:00 AM ET
      $VVOS
      Medical/Dental Instruments
      Health Care